Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq analysis of SCLC PDX models

ABSTRACT: RNAseq analysis of SCLC PDX models

PROVIDER: PRJEB50684 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR8445070_1.fastq.gz	Fastqsanger.gz
	ERR8445070_2.fastq.gz	Fastqsanger.gz
	ERR8445080_1.fastq.gz	Fastqsanger.gz
	ERR8445080_2.fastq.gz	Fastqsanger.gz
	ERR8445090_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 86

Similar Datasets

RNAseq analysis of SCLC PDX models

Project description:We investigated the gene expression changes in a library of small cell lung carcinoma (SCLC) patient-derived xenograft (PDX) models.

2022-02-07 | E-MTAB-11230 | biostudies-arrayexpress

RNAseq analysis of meso PDX models

Project description:RNAseq analysis of meso PDX models

| PRJEB53372 | ENA

RNA-seq of SCLC PDX models treated with EP

Project description:We report the correlation of transcript abundance with response to EP in 19 PDX models of SCLC

2018-03-06 | GSE110853 | GEO

RNA-seq of SCLC PDX models treated with EP

Project description:RNA-seq of SCLC PDX models treated with EP

| PRJNA434676 | ENA

RNAseq analysis of meso PDX models

Project description:We investigated the gene expression changes in a library of meso PDX models.

2022-06-17 | E-MTAB-11783 | biostudies-arrayexpress

RNAseq analysis of small cell lung cancer (SCLC) cell lines

Project description:Small cell lungcancer (SCLC) is an aggressive malignancy with dismal clinical outcomes, due inpart to the scarcity of post-relapse tissue samples. To understand more of transcriptional changes associated with treatment resistance, we performed RNAseq analysis of 61 SCLC cell lines.

2020-11-24 | GSE151904 | GEO

Comparison of 7 small cell lung cancer PDX models, cultured ex vivo, for response to LSD1 inhibitor RG6016/ORY1001

Project description:The goal of this study was to understand how the LSD1 inhibitor RG6016/ORY1001 leads to selective efficacy in subsets of small cell lung cancer. SCLC cell lines, PDX models studied ex vivo and studied in vivo were employed in this analysis

2019-06-10 | GSE103095 | GEO

The RNAseq of 79 small cell lung cancer (sclc) and 7 normal control

Project description:Even though small cell lung cancer (SCLC) has entered the age of broad genomic analysis, platinum-based chemotherapy remains the standard care for SCLC. Topotecan is the only approved agent for recurrent or progressive SCLC (1). In the absence of well-defined genomic biomarkers, clinical efficacy signals in genomically distinct subsets of SCLC could have been missed. Serine/Arginine Splicing Factor 1 (SRSF1) is a member of SR protein family. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation (2). Whole exome and transcriptome sequencing of primary tumor SCLC from 99 Chinese patients has identified SRSF1 DNA amplification and mRNA over-expression which predicts poor survival in Chinese SCLC patients. In vitro and in vivo studies have demonstrated that SRSF1 is essential for tumorigenecity of SCLC and plays a key role in DNA repair and chemo-sensitivity. We did RNAseq on 79 small cell lung cancer patients' tumor sample and 7 normal lung tissue. We normalized the RNAseq data and did differential expression analysis. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation.

2016-02-10 | E-GEOD-60052 | biostudies-arrayexpress

RNA-Seq Analysis of Paclitaxel-Resistant PDX Models in Mice

Project description:RNA-Seq Analysis of Paclitaxel-Resistant PDX Models in Mice

| PRJNA1139078 | ENA

RNAseq analysis of small cell lung cancer (SCLC) cell lines

Project description:RNAseq analysis of small cell lung cancer (SCLC) cell lines

| PRJNA637623 | ENA